BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22123160)

  • 1. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer.
    Takahashi H; Ohigashi H; Ishikawa O; Gotoh K; Yamada T; Nagata S; Tomita Y; Eguchi H; Doki Y; Yano M
    Ann Surg; 2012 Jan; 255(1):95-102. PubMed ID: 22123160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
    Takahashi H; Akita H; Tomokuni A; Kobayashi S; Ohigashi H; Fijiwara Y; Yano M; Sakon M; Ishikawa O
    Ann Surg; 2016 Dec; 264(6):1091-1097. PubMed ID: 27462960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
    Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G;
    J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
    Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
    Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancer.
    Takahashi H; Akita H; Wada H; Tomokuni A; Asukai K; Takahashi Y; Yanagimoto Y; Matsunaga T; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Yamamoto T; Nakanishi M; Shirayanagi M; Yamasaki T; Ohue M; Yano M; Sakon M; Ishikawa O
    Surgery; 2018 Dec; 164(6):1168-1177. PubMed ID: 30146098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
    Takahashi H; Ohigashi H; Gotoh K; Marubashi S; Yamada T; Murata M; Ioka T; Uehara H; Yano M; Ishikawa O
    Ann Surg; 2013 Dec; 258(6):1040-50. PubMed ID: 23799421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.
    Takahashi H; Akita H; Gotoh K; Kobayashi S; Marubashi S; Miyoshi N; Sugimura K; Motoori M; Kishi K; Noura S; Fujiwara Y; Ohue M; Ohigashi H; Yano M; Sakon M; Ishikawa O
    Surgery; 2015 Mar; 157(3):484-95. PubMed ID: 25444512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
    Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
    Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
    Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.
    Ozkok S; Demirci S; Yalman D; Zeytunlu M; Nart D; Yuzer Y; Coker A; Goker E
    Tumori; 2010; 96(4):560-7. PubMed ID: 20968135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
    Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
    Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
    Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG
    HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
    Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
    Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
    Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
    Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy.
    Kamachi H; Tsuruga Y; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamiyama T; Katoh N; Taketomi A
    In Vivo; 2018; 32(5):1183-1191. PubMed ID: 30150442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Strategies for preoperative downsizing in patients with local nonresectable pancreatic cancer].
    Combs SE; Habermehl D; Werner J; Büchler MW; Debus J
    Chirurg; 2011 Nov; 82(11):981-8. PubMed ID: 22008845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles.
    Lee SH; Kang CM; Kim H; Hwang HK; Song SY; Seong J; Kim MJ; Lee WJ
    Medicine (Baltimore); 2015 Dec; 94(52):e2168. PubMed ID: 26717359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
    Takahashi H; Ohigashi H; Ishikawa O; Eguchi H; Gotoh K; Yamada T; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K; Yano M
    Ann Surg; 2010 Mar; 251(3):461-9. PubMed ID: 20134315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
    Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.